HSBC Upgrades Teva Pharmaceutical (TEVA) to Overweight
More News related to TEVA
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
- Unusual 11 Mid-Day Movers 12/01: BIOF, ZN, GSIT, CAGC, RDN Higher; STAA, LTON, ZOOM, OVTI Lower
- Morning Movers 12/01: PEIX, SYMX, GSIT, HDY, GES, BPFH Higher; LTON, OVTI, PLX Lower
- Teva Pharma (TEVA) Submits BLA to U.S. FDA for XM02
- Teva Pharma (TEVA) and Codexis Sign Second Agreement This Year
More News related to Upgrades
- Knight (KNX), USA Truck (USAK), Werner (WERN) Higher Amid Avondale Upgrades
- William Blair Upgrades Manpower (MAN) Amid Strong Jobs Report
- Pritchard Capital Upgrades Geokinetics (GOK) to Buy
- Argus Upgrades ADC Telecommunications (ADCT) to Buy
- Oppenheimer Upgrades Akamai Tech (AKAM) to Outperform
HSBC upgrades Teva Pharmaceutical (Nasdaq: TEVA) from Neutral to Overweight.
Teva Pharmaceutical Industries Ltd. is a Global pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories.
Related Categories
UpgradesStocks Mentioned
+0.44Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
